Skip to content
2000
image of Potential of Small Molecule TAAR-1 Agonists for the Therapy of Neurodegenerative Psychosis: A Medicinal Chemistry Perspective

Abstract

This comprehensive review critically evaluates the emerging therapeutic potential of small-molecule Trace Amine-Associated Receptor 1 (TAAR-1) agonists as a novel, disease-modifying strategy for neurodegenerative psychosis. From a medicinal chemistry perspective, we assess Structure-Activity Relationship (SAR) data across a broad spectrum of chemotypes, including thyronamine analogues, pyrimidinone-benzimidazoles, guanfacine derivatives, thiophene-dihydropyran (Ulotaront), piperidine-carboxamides, sulfonamides, and biguanides. Our analysis establishes a unified strutural model centered on four essential structural elements, such as () a protonatable primary or secondary amine crucial for forming a salt bridge with the conserved Asp103 residue, () an aromatic or heteroaromatic core enabling pivotal π-stacking interactions with key hydrophobic residues (Phe186, Phe195, Trp264, Phe267, Phe268), () compact, meta-substituted hydrophobic groups (, methyl, chloro, isopropyl) that optimally occupy subpockets defined by Ile104, Ile290, or Val184, and () a strong preference for (S)-enantiomers to maximize binding complementarity. The compiled SAR reveals that agonist potency (EC values in the nM to μM range) and selectivity are critically dependent on these features, with auxiliary hydrogen-bond acceptors or donors (, near Ser107 or Tyr294) further stabilising the active receptor conformation. Conversely, structural deviations such as ortho-substitution, bulky N-alkylation, or R-enantiomers significantly compromise activity. Strategic bioisosteric replacements, such as methylene bridges and aminoethoxy chains, are highlighted for their role in enhancing metabolic stability. This robust pharmacophore underpins the rational design of advanced clinical candidates like Ulotaront, which demonstrate dual neuroprotective and symptomatic benefits over conventional antipsychotics, offering a clear roadmap for the development of next-generation TAAR-1-targeted therapeutics for complex neuropsychiatric disorders.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575435251251114091416
2026-01-02
2026-02-28

  • From This Site

    /content/journals/mrmc/10.2174/0113895575435251251114091416
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Mattiuzzi C. Lippi G. Cancer statistics: A comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). Eur. J. Public Health 2020 30 5 1026 1027 10.1093/eurpub/ckz216 31764976
    [Google Scholar]
  2. Raggi A. Monasta L. Beghi E. Caso V. Castelpietra G. Mondello S. Giussani G. Logroscino G. Magnani F.G. Piccininni M. Pupillo E. Ricci S. Ronfani L. Santalucia P. Sattin D. Schiavolin S. Toppo C. Traini E. Steinmetz J. Nichols E. Ma R. Vos T. Feigin V. Leonardi M. Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. J. Neurol. 2022 269 4 2080 2098 10.1007/s00415‑021‑10774‑5 34498172
    [Google Scholar]
  3. Timmis A. Townsend N. Gale C.P. Torbica A. Lettino M. Petersen S.E. Mossialos E.A. Maggioni A.P. Kazakiewicz D. May H.T. De Smedt D. Flather M. Zuhlke L. Beltrame J.F. Huculeci R. Tavazzi L. Hindricks G. Bax J. Casadei B. Achenbach S. Wright L. Vardas P. European society of cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). Eur. Heart J. Qual. Care Clin. Outcomes 2020 6 1 7 9 10.1093/ehjqcco/qcz065 31957796
    [Google Scholar]
  4. Choi B.C.K. Maza R.A. Mujica O.J. PAHO Technical Team. The pan american health organization-adapted hanlon method for prioritization of health programs. Rev. Panam. Salud Publ. 2019 43 1 10.26633/RPSP.2019.61 31363360
    [Google Scholar]
  5. Maher C. Ferreira G. Time to reconsider what Global Burden of Disease studies really tell us about low back pain. Ann. Rheum. Dis. 2022 81 3 306 308 10.1136/annrheumdis‑2021‑221173 34583922
    [Google Scholar]
  6. Espinoza S. Gainetdinov R.R. Neuronal Functions and Emerging Pharmacology of TAAR-1. In: Topics in Medicinal Chemistry. Cham Springer International Publishing 2014 175 194
    [Google Scholar]
  7. Revel F.G. Moreau J-L. Pouzet B. Mory R. Bradaia A. Buchy D. Metzler V. Chaboz S. Groebke Zbinden K. Galley G. Norcross R.D. Tuerck D. Bruns A. Morairty S.R. Kilduff T.S. Wallace T.L. Risterucci C. Wettstein J.G. Hoener M.C. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol. Psychiatry 2013 18 5 543 556 10.1038/mp.2012.57 22641180
    [Google Scholar]
  8. Koblan K.S. Kent J. Hopkins S.C. Krystal J.H. Cheng H. Goldman R. Loebel A.A. Non–D2-receptor-binding drug for the treatment of schizophrenia. New Engl. J. Med. 2020 382 16 1497 1506 10.1056/NEJMoa1911772 32294346
    [Google Scholar]
  9. Berry M.D. Gainetdinov R.R. Hoener M.C. Shahid M. Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. In: Pharmacol. Ther. 2017 180 161 180 10.1016/j.pharmthera.2017.07.002 28723415
    [Google Scholar]
  10. Espinoza S. Salahpour A. Masri B. Sotnikova T.D. Messa M. Barak L.S. Caron M.G. Gainetdinov R.R. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol. Pharmacol. 2011 80 3 416 425 10.1124/mol.111.073304 21670104
    [Google Scholar]
  11. Khokhar J.Y. Dwiel L.L. Henricks A.M. Doucette W.T. Green A.I. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr. Res. 2018 194 78 85 10.1016/j.schres.2017.04.016 28416205
    [Google Scholar]
  12. Revel F.G. Moreau J.L. Gainetdinov R.R. Ferragud A. Velázquez-Sánchez C. Sotnikova T.D. Morairty S.R. Harmeier A. Groebke Zbinden K. Norcross R.D. Bradaia A. Kilduff T.S. Biemans B. Pouzet B. Caron M.G. Canales J.J. Wallace T.L. Wettstein J.G. Hoener M.C. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol. Psychiatry 2012 72 11 934 942 10.1016/j.biopsych.2012.05.014 22705041
    [Google Scholar]
  13. Accorroni A. Zucchi R. Trace amine-associated receptors. Trace Amines and Neurological Disorders. Elsevier 2016 151 164 10.1016/B978‑0‑12‑803603‑7.00011‑2
    [Google Scholar]
  14. Goff D.C. Promising evidence of antipsychotic efficacy without dopamine d2-receptor binding. New Engl. J. Med. 2020 382 16 1555 1556 10.1056/NEJMe2001508 32294351
    [Google Scholar]
  15. Demjaha A. Murray R.M. McGuire P.K. Kapur S. Howes O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am. J. Psychiatry 2012 169 11 1203 1210 10.1176/appi.ajp.2012.12010144 23034655
    [Google Scholar]
  16. Kim E. Howes O.D. Veronese M. Beck K. Seo S. Park J.W. Lee J.S. Lee Y.S. Kwon J.S. Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: An [18F]DOPA PET study. Neuropsychopharmacology 2017 42 4 941 950 10.1038/npp.2016.258 27857125
    [Google Scholar]
  17. Murray R.M. Quattrone D. Natesan S. van Os J. Nordentoft M. Howes O. Di Forti M. Taylor D. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br. J. Psychiatry 2016 209 5 361 365 10.1192/bjp.bp.116.182683 27802977
    [Google Scholar]
  18. Nair P.C. McKinnon R.A. Miners J.O. Bastiampillai T. Binding of clozapine to the GABAB receptor: Clinical and structural insights. Mol. Psychiatry 2020 25 9 1910 1919 10.1038/s41380‑020‑0709‑5 32203158
    [Google Scholar]
  19. Nair P.C. Miners J.O. McKinnon R.A. Langmead C.J. Gregory K.J. Copolov D. Chan S.K.W. Bastiampillai T. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Mol. Psychiatry 2022 27 1 88 94 10.1038/s41380‑021‑01250‑7 34376825
    [Google Scholar]
  20. Jones P. Dedic N. Hopkins S. Synan C. Koblan K.P. 163 SEP-363856, a novel psychotropic agent with a unique, non-d2 mechanism of action. Eur. Neuropsychopharmacol. 2019 29 S126 S127 10.1016/j.euroneuro.2019.09.209
    [Google Scholar]
  21. Liberles S.D. Buck L.B. A second class of chemosensory receptors in the olfactory epithelium. Nature 2006 442 7103 645 650 10.1038/nature05066 16878137
    [Google Scholar]
  22. Xu Z. Li Q. TAAR agonists. Cell. Mol. Neurobiol. 2020 40 2 257 272 10.1007/s10571‑019‑00774‑5 31848873
    [Google Scholar]
  23. Espinoza S. TAAR-1 modulates cortical glutamate NMDA receptor function. Intrinsic Activit. 2016 4 2 A18 10.25006/IA.4.S2‑A18.75
    [Google Scholar]
  24. Borowsky B. Adham N. Jones K.A. Raddatz R. Artymyshyn R. Ogozalek K.L. Durkin M.M. Lakhlani P.P. Bonini J.A. Pathirana S. Boyle N. Pu X. Kouranova E. Lichtblau H. Ochoa F.Y. Branchek T.A. Gerald C. Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proc. Natl0 Acad. Sci. USA 2001 98 16 8966 8971 10.1073/pnas.151105198 11459929
    [Google Scholar]
  25. Bunzow J.R. Sonders M.S. Arttamangkul S. Harrison L.M. Zhang G. Quigley D.I. Darland T. Suchland K.L. Pasumamula S. Kennedy J.L. Olson S.B. Magenis R.E. Amara S.G. Grandy D.K. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 2001 60 6 1181 1188 10.1124/mol.60.6.1181 11723224
    [Google Scholar]
  26. Hoener M.C. Lindemann L. Meyer C.A. Jeanneau K. Bradaia A. Ozmen L. Bettler B. Wettstein J.G. Borroni E. Moreau J.L. Trace amine‐associated receptor 1 (TAAR1) modulates dopaminergic activity. FASEB J. 2008 22 S1 10.1096/fasebj.22.1_supplement.1126.1
    [Google Scholar]
  27. Li Q. Tachie-Baffour Y. Liu Z. Baldwin M.W. Kruse A.C. Liberles S.D. Non-classical amine recognition evolved in a large clade of olfactory receptors. eLife 2015 4 e10441 10.7554/eLife.10441 26519734
    [Google Scholar]
  28. Glyakina A.V. Pavlov C.D. Sopova J.V. Gainetdinov R.R. Leonova E.I. Galzitskaya O.V. Search for structural basis of interactions of biogenic amines with human TAAR1 and TAAR6 receptors. Int. J. Mol. Sci. 2021 23 1 209 10.3390/ijms23010209 35008636
    [Google Scholar]
  29. van der Westhuizen E.T. Valant C. Sexton P.M. Christopoulos A. Endogenous allosteric modulators of G protein-coupled receptors. J. Pharmacol. Exp. Ther. 2015 353 2 246 260 10.1124/jpet.114.221606 25650376
    [Google Scholar]
  30. Eyun S. Moriyama H. Hoffmann F.G. Moriyama E.N. Molecular evolution and functional divergence of trace amine–associated receptors. PLoS One 2016 11 3 e0151023 10.1371/journal.pone.0151023 26963722
    [Google Scholar]
  31. Grus W.E. Zhang J. Distinct evolutionary patterns between chemoreceptors of 2 vertebrate olfactory systems and the differential tuning hypothesis. Mol. Biol. Evol. 2008 25 8 1593 1601 10.1093/molbev/msn107 18460446
    [Google Scholar]
  32. Babusyte A. Kotthoff M. Fiedler J. Krautwurst D. Biogenic amines activate blood leukocytes via trace amine-associated receptors TAAR1 and TAAR2. J. Leukoc. Biol. 2013 93 3 387 394 10.1189/jlb.0912433 23315425
    [Google Scholar]
  33. Ito J. Ito M. Nambu H. Fujikawa T. Tanaka K. Iwaasa H. Tokita S. Anatomical and histological profiling of orphan G-protein-coupled receptor expression in gastrointestinal tract of C57BL/6J mice. Cell Tissue Res. 2009 338 2 257 269 10.1007/s00441‑009‑0859‑x 19763624
    [Google Scholar]
  34. Kubo H. Shibato J. Saito T. Ogawa T. Rakwal R. Shioda S. Unraveling the rat intestine, spleen and liver genome-wide transcriptome after the oral administration of lavender oil by a two-color dye-swap DNA microarray approach. PLoS One 2015 10 7 e0129951 10.1371/journal.pone.0129951 26161641
    [Google Scholar]
  35. Nelson D.A. Tolbert M.D. Singh S.J. Bost K.L. Expression of neuronal trace amine-associated receptor (Taar) mRNAs in leukocytes. J. Neuroimmunol. 2007 192 1-2 21 30 10.1016/j.jneuroim.2007.08.006 17900709
    [Google Scholar]
  36. Underhill S.M. Hullihen P.D. Chen J. Fenollar-Ferrer C. Rizzo M.A. Ingram S.L. Amara S.G. Amphetamines signal through intracellular TAAR1 receptors coupled to Gα13 and GαS in discrete subcellular domains. Mol. Psychiatry 2021 26 4 1208 1223 10.1038/s41380‑019‑0469‑2 31399635
    [Google Scholar]
  37. Brahmachary R.L. Dutta J. Phenylethylamine as a biochemical marker of tiger. Z. Naturforsch. C J. Biosci. 1979 34 7-8 632 633 10.1515/znc‑1979‑7‑824 158904
    [Google Scholar]
  38. Harmeier A. Obermueller S. Meyer C.A. Revel F.G. Buchy D. Chaboz S. Dernick G. Wettstein J.G. Iglesias A. Rolink A. Bettler B. Hoener M.C. Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers. Eur. Neuropsychopharmacol. 2015 25 11 2049 2061 10.1016/j.euroneuro.2015.08.011 26372541
    [Google Scholar]
  39. Kaupp U.B. Olfactory signalling in vertebrates and insects: differences and commonalities. Nat. Rev. Neurosci. 2010 11 3 188 200 10.1038/nrn2789 20145624
    [Google Scholar]
  40. Grandy D.K. Trace amine-associated receptor 1—Family archetype or iconoclast? Pharmacol. Ther. 2007 116 3 355 390 10.1016/j.pharmthera.2007.06.007 17888514
    [Google Scholar]
  41. Bradaia A. Trube G. Stalder H. Norcross R.D. Ozmen L. Wettstein J.G. Pinard A. Buchy D. Gassmann M. Hoener M.C. Bettler B. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl. Acad. Sci. USA 2009 106 47 20081 20086 10.1073/pnas.0906522106 19892733
    [Google Scholar]
  42. Yang W. Munhall A.C. Johnson S.W. Dopamine evokes a trace amine receptor-dependent inward current that is regulated by AMP kinase in Substantia nigra dopamine neurons. Neuroscience 2020 427 77 91 10.1016/j.neuroscience.2019.11.044 31883822
    [Google Scholar]
  43. Leo D. Mus L. Espinoza S. Hoener M.C. Sotnikova T.D. Gainetdinov R.R. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: Role of D2 dopamine autoreceptors. Neuropharmacology 2014 81 283 291 10.1016/j.neuropharm.2014.02.007 24565640
    [Google Scholar]
  44. Chiellini G. Nesi G. Digiacomo M. Malvasi R. Espinoza S. Sabatini M. Frascarelli S. Laurino A. Cichero E. Macchia M. Gainetdinov R.R. Fossa P. Raimondi L. Zucchi R. Rapposelli S. Design, Synthesis, and evaluation of thyronamine analogues as novel potent mouse trace amine associated receptor 1 (m TAAR1). Agonists. J. Med. Chem. 2015 58 12 5096 5107 10.1021/acs.jmedchem.5b00526 26010728
    [Google Scholar]
  45. Hart M.E. Suchland K.L. Miyakawa M. Bunzow J.R. Grandy D.K. Scanlan T.S. Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. J. Med. Chem. 2006 49 3 1101 1112 10.1021/jm0505718 16451074
    [Google Scholar]
  46. Tan E.S. Groban E.S. Jacobson M.P. Scanlan T.S. Toward deciphering the code to aminergic G protein-coupled receptor drug design. Chem. Biol. 2008 15 4 343 353 10.1016/j.chembiol.2008.03.004 18420141
    [Google Scholar]
  47. Grossi G. Scarano N. Musumeci F. Tonelli M. Kanov E. Carbone A. Fossa P. Gainetdinov R.R. Cichero E. Schenone S. discovery of a novel chemo-type for TAAR1 agonism via molecular modeling. Molecules 2024 29 8 1739 10.3390/molecules29081739 38675561
    [Google Scholar]
  48. Galley G. Beurier A. Décoret G. Goergler A. Hutter R. Mohr S. Pähler A. Schmid P. Türck D. Unger R. Zbinden K.G. Hoener M.C. Norcross R.D. Discovery and characterization of 2-aminooxazolines as highly potent, selective, and orally active TAAR1 agonists. ACS Med. Chem. Lett. 2016 7 2 192 197 10.1021/acsmedchemlett.5b00449 26985297
    [Google Scholar]
  49. Dorahy G. Chen J.Z. Balle T. Computer-aided drug design towards new psychotropic and neurological drugs. Molecules 2023 28 3 1324 10.3390/molecules28031324 36770990
    [Google Scholar]
  50. Cichero E. Francesconi V. Casini B. Casale M. Kanov E. Gerasimov A.S. Sukhanov I. Savchenko A. Espinoza S. Gainetdinov R.R. Tonelli M. Discovery of guanfacine as a novel TAAR1 agonist: A combination strategy through molecular modeling studies and biological assays. Pharmaceuticals 2023 16 11 1632 10.3390/ph16111632 38004497
    [Google Scholar]
  51. Jumper J. Evans R. Pritzel A. Green T. Figurnov M. Ronneberger O. Tunyasuvunakool K. Bates R. Žídek A. Potapenko A. Bridgland A. Meyer C. Kohl S.A.A. Ballard A.J. Cowie A. Romera-Paredes B. Nikolov S. Jain R. Adler J. Back T. Petersen S. Reiman D. Clancy E. Zielinski M. Steinegger M. Pacholska M. Berghammer T. Bodenstein S. Silver D. Vinyals O. Senior A.W. Kavukcuoglu K. Kohli P. Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature 2021 596 7873 583 589 10.1038/s41586‑021‑03819‑2 34265844
    [Google Scholar]
  52. Varadi M. Anyango S. Deshpande M. Nair S. Natassia C. Yordanova G. Yuan D. Stroe O. Wood G. Laydon A. Žídek A. Green T. Tunyasuvunakool K. Petersen S. Jumper J. Clancy E. Green R. Vora A. Lutfi M. Figurnov M. Cowie A. Hobbs N. Kohli P. Kleywegt G. Birney E. Hassabis D. Velankar S. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022 50 D1 D439 D444 10.1093/nar/gkab1061 34791371
    [Google Scholar]
  53. Cichero E. Espinoza S. Franchini S. Guariento S. Brasili L. Gainetdinov R.R. Fossa P. Further insights into the pharmacology of the human trace amine-associated receptors: Discovery of novel ligands for TAAR1 by a virtual screening approach. Chem. Biol. Drug Des. 2014 84 6 712 720 10.1111/cbdd.12367 24894156
    [Google Scholar]
  54. Sorbi C. Franchini S. Tait A. Prandi A. Gallesi R. Angeli P. Marucci G. Pirona L. Poggesi E. Brasili L. 1,3-Dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors. ChemMedChem 2009 4 3 393 399 10.1002/cmdc.200800277 19152363
    [Google Scholar]
  55. Brasili L. Sorbi C. Franchini S. Manicardi M. Angeli P. Marucci G. Leonardi A. Poggesi E. 1,3-dioxolane-based ligands as a novel class of alpha1-adrenoceptor antagonists. J. Med. Chem. 2003 46 8 1504 1511 10.1021/jm021078o 12672251
    [Google Scholar]
  56. Krasavin M. Peshkov A.A. Lukin A. Komarova K. Vinogradova L. Smirnova D. Kanov E.V. Kuvarzin S.R. Murtazina R.Z. Efimova E.V. Gureev M. Onokhin K. Zakharov K. Gainetdinov R.R. Discovery and In vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders. Int. J. Mol. Sci. 2022 23 19 11579 10.3390/ijms231911579 36232878
    [Google Scholar]
  57. Guariento S. Tonelli M. Espinoza S. Gerasimov A.S. Gainetdinov R.R. Cichero E. Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists. Eur. J. Med. Chem. 2018 146 171 184 10.1016/j.ejmech.2018.01.059 29407948
    [Google Scholar]
  58. Madhavi Sastry G. Adzhigirey M. Day T. Annabhimoju R. Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 2013 27 3 221 234 10.1007/s10822‑013‑9644‑8 23579614
    [Google Scholar]
  59. Heffernan M.L.R. Herman L.W. Brown S. Jones P.G. Shao L. Hewitt M.C. Campbell J.E. Dedic N. Hopkins S.C. Koblan K.S. Xie L. Ulotaront: A TAAR1 Agonist for the treatment of schizophrenia. ACS Med. Chem. Lett. 2022 13 1 92 98 10.1021/acsmedchemlett.1c00527 35047111
    [Google Scholar]
  60. Gainetdinov R.R. Hoener M.C. Berry M.D. Trace amines and their receptors. Pharmacol. Rev. 2018 70 3 549 620 10.1124/pr.117.015305 29941461
    [Google Scholar]
  61. Rutigliano G. Accorroni A. Zucchi R. The case for TAAR1 as a modulator of central nervous system function. Front. Pharmacol. 2018 8 987 10.3389/fphar.2017.00987 29375386
    [Google Scholar]
  62. Zhou Z. Zhang W. Zhao F. Gao N. Tao S. Wang N. Jiang J.J. Yang F. Sun J.P. Liu X. Kang D. In silico discovery of novel potent trace amine-associated receptor taar1 agonists as promising drug candidates for the treatment of schizophrenia. J. Med. Chem. 2025 68 10 10255 10267 10.1021/acs.jmedchem.5c00432 40338903
    [Google Scholar]
  63. Shang P. Rong N. Jiang J.J. Cheng J. Zhang M.H. Kang D. Qi L. Guo L. Yang G.M. Liu Q. Zhou Z. Li X.B. Zhu K.K. Meng Q.B. Han X. Yan W. Kong Y. Yang L. Wang X. Lei D. Feng X. Liu X. Yu X. Wang Y. Li Q. Shao Z.H. Yang F. Sun J.P. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. Cell 2023 186 24 5347 5362.e24 10.1016/j.cell.2023.10.014 37963465
    [Google Scholar]
  64. Xu Z. Guo L. Yu J. Shen S. Wu C. Zhang W. Zhao C. Deng Y. Tian X. Feng Y. Hou H. Su L. Wang H. Guo S. Wang H. Wang K. Chen P. Zhao J. Zhang X. Yong X. Cheng L. Liu L. Yang S. Yang F. Wang X. Yu X. Xu Y. Sun J.P. Yan W. Shao Z. Ligand recognition and G-protein coupling of trace amine receptor TAAR1. Nature 2023 624 7992 672 681 10.1038/s41586‑023‑06804‑z 37935376
    [Google Scholar]
  65. Lu J. Yu P. Wang Y. Dai Y. Wang W. Liu C. Dong L. Lei H. Yang Y. Wang L. Zou F. Deng X. Wang B. Wei S. Ma M. Wang H. Ye L. Zhang J. Tian J. Rational design of the first dual agonist at trace amine-associated receptor 1 and 5-HT2C receptors based on binding pocket similarity for the treatment of schizophrenia and alzheimer’s disease-related psychosis. J. Med. Chem. 2025 68 7 7082 7105 10.1021/acs.jmedchem.4c02291 40159850
    [Google Scholar]
  66. Chagraoui A. Thibaut F. Skiba M. Thuillez C. Bourin M. 5-HT2C receptors in psychiatric disorders: A review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016 66 120 135 10.1016/j.pnpbp.2015.12.006 26739950
    [Google Scholar]
  67. Di Giovanni G. De Deurwaerdère P. New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders. Pharmacol. Ther. 2016 157 125 162 10.1016/j.pharmthera.2015.11.009 26617215
    [Google Scholar]
  68. Wang Y. Liu Z. Lu J. Wang W. Wang L. Yang Y. Wang H. Ye L. Zhang J. Tian J. Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment. Front. Pharmacol. 2023 14 1161964 10.3389/fphar.2023.1161964 37153799
    [Google Scholar]
  69. Miller G.M. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurochem. 2011 116 2 164 176 10.1111/j.1471‑4159.2010.07109.x 21073468
    [Google Scholar]
  70. Tonelli M. Espinoza S. Gainetdinov R.R. Cichero E. Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies. Eur. J. Med. Chem. 2017 127 781 792 10.1016/j.ejmech.2016.10.058 27823885
    [Google Scholar]
  71. Glennon R.A. Daoud M.K. Dukat M. Teitler M. Herrick-Davis K. Purohit A. Syed H. Arylguanidine and arylbiguanide binding at 5-HT3 serotonin receptors: A QSAR study. Bioorg. Med. Chem. 2003 11 20 4449 4454 10.1016/S0968‑0896(03)00488‑7 13129581
    [Google Scholar]
  72. Raab S. Wang H. Uhles S. Cole N. Alvarez-Sanchez R. Künnecke B. Ullmer C. Matile H. Bedoucha M. Norcross R.D. Ottaway-Parker N. Perez-Tilve D. Conde Knape K. Tschöp M.H. Hoener M.C. Sewing S. Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. Mol. Metab. 2016 5 1 47 56 10.1016/j.molmet.2015.09.015 26844206
    [Google Scholar]
  73. Vannabouathong C. Picheca L. Dyrda P. Trace amine-associated receptor 1 agonists for schizophrenia. Cancr J. Health. Technol, 2022 2 7 10.51731/cjht.2022.392 38723121
    [Google Scholar]
  74. A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms. NCT03669640 Available from: https://clinicaltrials.gov/study/NCT03669640
/content/journals/mrmc/10.2174/0113895575435251251114091416
Loading
Potential of Small Molecule TAAR-1 Agonists for the Therapy of Neurodegenerative Psychosis: A Medicinal Chemistry Perspective
Bentham Science Publishers ; https://doi.org/10.2174/0113895575435251251114091416
/content/journals/mrmc/10.2174/0113895575435251251114091416
/content/journals/mrmc/10.2174/0113895575435251251114091416
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Trace amine-associated receptor 1 (TAAR-1) ; structure activity relationship (SAR) ; TAAR-1 agonist ; schizophrenia ; neuroprotection ; neurodegenerative psychosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test